#1

heart diseases is the #1 cause of death worldwide

1 in 10

experience prolonged fatigue

15%

of all deaths are related to cancer

44 million

living worldwide with Alzheimer's or a related dementia

5%

of worldwide population has diabetes

1.9 billion

adults are overweight or obese

GREAT MEDICAL IDEAS AND CUTTING EDGE BIOTECHNOLOGY WILL HELP TO DECREASE THESE NUMBERS

 
About

Naturalis Nordica is a privately funded initiative based in the capital of Scandinavia, Stockholm. Naturalis Nordica sees its role as a catalyst for growth and research within the pharmaceutical, biomedical and biotechnological fields, but also in companies within health and food supplements. The focus on these subjects arises from the potential to have a significant impact.

Northern Europe is a leading area within biomedicine and pharmaceuticals, as well as a hot spot for new technologies and start-ups.

The Naturalis Nordica team has extensive knowledge in all areas from retail and distribution to supply-chain and manufacturing. This expertise is required to develop an effective methodology for driving projects from ideas to products in the least time possible. This is especially important in such experimental areas.

If you’d like to come in contact with us to discuss a potential investment, please don’t hesitate to present your company.
Our Ambition

Naturalis Nordica’s mission is to discover companies developing breakthrough technologies that have the capacity to contribute to an improved daily life. By providing support to these companies at the early stages of research or commercialization. We intend to ensure their success and, if necessary, amplify it on a global scale.

We commit to our mission by acquiring, funding or just supporting promoters of promising technologies within our field of interest.

At Naturalis Nordica we put particular emphasis on pharmaceutical, biomedical and biotechnological firms based in Northern Europe as well as the United States.

Board of directors
Barbara Minati is founder, investor and CEO of Naturalis Nordica.

She has an entrepreneurial background having worked in international organizations across diversified industries.

After a close member of her family was diagnosed with a rare disease, she decided to drastically change career and dived into the world of medicine, studying and experimenting with innovative treatments.

With Naturalis Nordica she intends to help companies realize their potential.

Barbara continues to apply the broad experience from her previous positions into this new realm.
Andrea Doglioni Majer is founder and investor.

He is an experienced and successful entrepreneur owning, managing and financing companies in different industries around the world, including several Asian countries.

Andrea recognizes the strength of Naturalis Nordica’s vision and aims to bring his organizational expertise into the company.

He has had personal experience in commercializing products in highly regulated industries. Furthermore, he has extensive experience and knowledge of IP protection.
Fredrik Ylve is a strategic advisor.

He is an entrepreneur and management consultant.

Fredrik has extensive experience helping both national and global companies in a broad range of industries becoming more competitive and successful.

Fredrik is excited to bring great ideas to a broader consumer market.

Through his broad background, Fredrik contributes to the future success of Naturalis Nordica’s investments.

He has an extensive experience in executing growth strategies and making the global supply chain more cost effective.
Advisory board members

To ensure success for our investments we have established a cross-functional Advisory Board consisting of prominent experts within their fields. Through the Advisory Board members, we cover all relevant areas to ensure a successful commercialization of products on their path from research to distribution.

Lucia Aronica holds a PhD in Life Science and is currently a researcher in Epigenetics and Nutrition at Stanford University.

She is working with Prof Christopher Gardner on the largest study ever undertaken to compare low-carb vs. low fat with the goal of understanding how diet affects gene activity through epigenetic modifications.

Dr. Aronica has recently been awarded a Marie-Curie Fellowship, Europe’s most competitive research grant, scoring #1 among the applicants in the entire Life Sciences panel.

Previously, she received a Hertha Firnberg award from the Austrian Science Funds, and became project leader at the Vienna-Biocenter in Austria. She has also received science communication awards from Europe PubMed Central and FameLab International.

Dr. Aronica has research experience from the University of Oxford, University Federico II of Naples, University of Vienna, University of Southern California, and Stanford University.

She has published research papers in top-ranked peer reviewed journals such as Cell, Genes and Development, the EMBO Journal and Nucleic Acid Research.
Anna Levander is CSO at Envirotainer, the global market leader in secure cold chain solutions for the pharmaceutical supply chain.

Previously Ms. Levander worked at Thermo Fischer Scientific where she held positions as VP Sales, Europe and VP Sales & Marketing, Europe. She has also held various roles at Abbott, especially within the Diabetes Care business unit. Furthermore she has been product and portfolio manager at Pfizer US.

Ms. Levander has been a board member of Ellen AB (medical devices) and Medcore AB (medical device distributor). She has also been chairman of the industry group Diabetes at Swedish Medtech, an advisory board member to Trygga Barnen (foundation), and a member of the steering committee for Project KI 2.0 (entrepreneurship at Karolinska Institutet, one of the world´s leading medical universities)

Ms. Levander holds a MSc in Economics and Business Administration from Stockholm School of Economics. With 16 years experience from various roles in the pharmaceutical industry she brings invaluable competence to Naturalis Nordica.
Jan Marsal is an MD/PhD of Gastroenterology/Immunology at Lund University and Skane University Hospital (Sweden).

Dr. Marsal works as a clinical gastroenterologist with focus on Inflammatory Bowel Disease (IBD) and endoscopy, and as a researcher focusing on therapy-optimization in IBD and pre-clinical/translational immunology. Currently Dr. Marsal chairs a group developing national Swedish guidelines for management of IBD during pregnancy. He also chairs a national research-group focusing on therapies in IBD.

Previously Dr. Marsal has been part of an expert-group writing national guidelines for IBD-treatment for the Swedish Medical Products Agency, and has been an advisory to several companies in stages 2-4 of pharmaceutical development including AbbVie, BMS, Ferring, Otsuka, Pfizer, Takeda, Tillotts, and UCB Pharma.

Dr. Marsal has research experience from Lund University and Harvard Medical School (Boston, US), and has published research-articles in the following scientific journals: Immunity, Journal of Clinical Investigation, Current Biology, Blood, Rheumatology, Mucosal Immunology, Journal of Internal Medicine, and several others.
Contact us

Thanks for contacting us, we will respond you as soon as possible.